Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'
Rhea-AI Summary
Veeva Systems (NYSE: VEEV) and Boehringer Ingelheim have successfully launched the 'One Medicine Platform' powered by Veeva Development Cloud, marking a significant milestone in their collaboration announced in March 2022. The platform unifies data and processes across clinical, regulatory, and quality functions.
As one of the top 20 biopharma companies, Boehringer Ingelheim is leveraging this unified platform to streamline product development, optimize trial efficiency, and enhance collaboration with research sites. The implementation enables seamless data connectivity across functions, aiming to accelerate the delivery of new treatments for currently incurable diseases.
The Veeva Development Cloud serves as the technology foundation, integrating clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Positive
- Strategic partnership with top 20 biopharma company Boehringer Ingelheim
- Successful implementation of comprehensive Development Cloud platform
- Expansion of Veeva's presence in clinical trial technology market
Negative
- None.
News Market Reaction
On the day this news was published, VEEV declined 3.32%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases
INGELHEIM,
"Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance."
"By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."
Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Additional Information
For more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloud
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Deivis Mercado | Jeremy Whittaker |
View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-partners-with-veeva-to-launch-one-medicine-platform-302397880.html
SOURCE Veeva Systems
FAQ
What is the One Medicine Platform launched by Boehringer Ingelheim and Veeva (VEEV)?
How does the Veeva (VEEV) Development Cloud benefit clinical trials?
When did Boehringer Ingelheim and Veeva (VEEV) first announce their One Medicine collaboration?
What are the key components integrated in Veeva's (VEEV) Development Cloud platform?
